Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results hospitalization Esymptomatic Covid-19 Esevere COVID-19 occurrence E

COVID-19 prophylaxis (excluding children) meta-analysis

PROFISCOV (SinoVac Brazil)
RCTCoronaVac (SinoVac)placeboCOVID-19 prophylaxis (excluding children)NA
6195/6201 suggested -75% -90%
Sinovac Turkish Trial unpublished
RCTCoronaVac (SinoVac)placeboCOVID-19 prophylaxis (excluding children)NA
752/570 suggested -90% -75%
Faria OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)critical
-/- suggested -46%
Chile study (Aaros ) unpublished OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested -76% -60% -80%
Hitchings OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)serious
393/393 no results -40%
Wan OBSCoronaVac (SinoVac)controlCOVID-19 prophylaxis (excluding children)critical
-/- safety concern
DESCCoronaVac (SinoVac)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).